Noble Life Sciences, Inc. has announced a partnership with BioFactura, Inc. (Rockville, MD), a developer and provider of proprietary technologies and services for production of biological.
The collaboration expands Noble’s CRO services to include the development and production of monoclonal antibody and other protein-based drugs.
Through the partnership, Noble becomes the exclusive commercial contract services provider of BioFactura’s technologies and capabilities.
BioFactura’s capabilities enable rapid, scalable, high potency production of protein drug candidates in mammalian and microbial systems, from development of expression vectors and cell lines to growth medium optimization, protein purification, and process scale-up.
BioFactura’s StableFast™ biomanufacturing platform is a unique, patented system for developing stable mammalian NS0 cell lines that can generate over one gram of protein in eight weeks.
“This relationship allows Noble to offer end-to-end preclinical biopharmaceutical development services - from cell line development to protein production, in vitro screening, in vivo efficacy and pharmacodynamics testing and biomarker development” said Alain Cappeluti, Noble Life Sciences President.
“We are looking forward to working with Noble to provide drug developers wider access to our unique capabilities,” said Darryl Sampey, BioFactura’s President and CEO.
Sampey continued, “This partnership creates an excellent synergy between Noble’s experienced scientific drug development team and BioFactura’s protein bioprocessing expertise.”